MCM
CLB icon

Manchester Capital Management’s Core Laboratories CLB Stock Holding History

Manchester Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54
Closed -$907 – 1319
2026
Q1 		$907 Hold
54
– – ﹤0.01% 1151
2025
Q4 		$866 Hold
54
– – ﹤0.01% 1162
2025
Q3 		$668 Hold
54
– – ﹤0.01% 1180
2025
Q2 		$623 Buy
+54
New +$640 ﹤0.01% 1096
2015
Q1 		– Sell
-675
Closed -$81K – 592
2014
Q4 		$81K Buy
+675
New +$88.7K 0.01% 604

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Manchester Capital Management's CLB Position: Q2 2026 in Review

Manchester Capital Management sold out of Core Laboratories (CLB) in Q2 2026, closing a stake of 54 shares — an estimated $907 sold.

Manchester Capital Management first reported a position in CLB in Q4 2014 and held it in 5 quarters. The position peaked at $81K in Q4 2014. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • Manchester Capital Management reported no remaining Core Laboratories position as of Q2 2026 after selling out during the quarter.
  • Manchester Capital Management sold 54 Core Laboratories shares in Q2 2026, an estimated $907.
  • Manchester Capital Management first reported a position in Core Laboratories in Q4 2014 and held it in 5 quarters.
  • Manchester Capital Management's Core Laboratories position peaked at $81K in Q4 2014.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.